Ocuphire Announces Publication in the Journal of Cellular Signaling Featuring its Oral Ref-1 Inhibitor APX3330 in Phase 2 Trial for the Treatment of Retinal Disease Jul 22, 2021
Processa Pharmaceuticals Enters Into A Licensing Agreement With Ocuphire Pharma, Inc., For The Development Of RX-3117 Jun 17, 2021
Ocuphire Announces Closing of $15 Million Registered Direct Offering Priced At-the-Market Jun 8, 2021
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Jun 4, 2021
Ocuphire to Host Key Opinion Leader Event on Nyxol® as a Potential New Treatment Option for Reversing Pharmacologically Induced Mydriasis May 20, 2021
